| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2021-06-19 18:41:58 UTC |
|---|
| Updated at | 2025-02-13 00:03:31 UTC |
|---|
| NP-MRD ID | NP0026938 |
|---|
| Natural Product DOI | https://doi.org/10.57994/3715 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Silvestrol |
|---|
| Provided By | JEOL Database |
|---|
| Description | Silvestrol is a secondary metabolite. Secondary metabolites are metabolically or physiologically non-essential metabolites that may serve a role as defense or signalling molecules. In some cases they are simply molecules that arise from the incomplete metabolism of other secondary metabolites. Silvestrol is found in Aglaia foveolata and Aglaia silvestris. Silvestrol was first documented in 2021 (PMID: 34353608). Based on a literature review a small amount of articles have been published on silvestrol (PMID: 34104125) (PMID: 34058216) (PMID: 34001163). |
|---|
| Structure | [H]OC([H])([H])[C@@]([H])(O[H])[C@]1([H])O[C@@]([H])(OC2=C([H])C(OC([H])([H])[H])=C3C(O[C@@]4(C5=C([H])C([H])=C(OC([H])([H])[H])C([H])=C5[H])[C@]([H])(C5=C([H])C([H])=C([H])C([H])=C5[H])[C@@]([H])(C(=O)OC([H])([H])[H])[C@@]([H])(O[H])[C@@]34O[H])=C2[H])[C@]([H])(OC([H])([H])[H])OC1([H])[H] InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Silvestrol | ChEBI |
|
|---|
| Chemical Formula | C34H38O13 |
|---|
| Average Mass | 654.6650 Da |
|---|
| Monoisotopic Mass | 654.23124 Da |
|---|
| IUPAC Name | methyl (2S,3R,4R,5S,6R)-10-{[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy}-2,3-dihydroxy-12-methoxy-6-(4-methoxyphenyl)-5-phenyl-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-triene-4-carboxylate |
|---|
| Traditional Name | methyl (2S,3R,4R,5S,6R)-10-{[(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl]oxy}-2,3-dihydroxy-12-methoxy-6-(4-methoxyphenyl)-5-phenyl-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-triene-4-carboxylate |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H]OC([H])([H])[C@@]([H])(O[H])[C@]1([H])O[C@@]([H])(OC2=C([H])C(OC([H])([H])[H])=C3C(O[C@@]4(C5=C([H])C([H])=C(OC([H])([H])[H])C([H])=C5[H])[C@]([H])(C5=C([H])C([H])=C([H])C([H])=C5[H])[C@@]([H])(C(=O)OC([H])([H])[H])[C@@]([H])(O[H])[C@@]34O[H])=C2[H])[C@]([H])(OC([H])([H])[H])OC1([H])[H] |
|---|
| InChI Identifier | InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1 |
|---|
| InChI Key | GVKXFVCXBFGBCD-QKDMMWSPSA-N |
|---|
| Experimental Spectra |
|---|
|
| | Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
|---|
| NOESY NMR | [1H, 1H] NMR Spectrum (2D, 400 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | COSY NMR | [1H, 1H] NMR Spectrum (2D, 400 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 400 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | HSQC NMR | [1H, 13C] NMR Spectrum (2D, 400 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, CDCl3, experimental) | rakotondraibe.1@osu.edu | The Ohio State University | Harinantenaina Liva Rakotondraibe | 2025-02-11 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 500 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 100 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 200 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 300 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 600 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 700 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 800 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 900 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, CDCl3, simulated) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Classification | Not classified |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Nilewski C, Michels TD, Packard GK, Xiang AX, Sprengeler PA, Eam B, Fish S, Thompson PA, Wegerski CJ, Nevarez A, Clarine J, Sperry S, Ernst JT, Reich SH: 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties. Bioorg Med Chem Lett. 2021 Sep 1;47:128111. doi: 10.1016/j.bmcl.2021.128111. Epub 2021 Aug 2. [PubMed:34353608 ]
- Greger H: Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans from Aglaia species (Meliaceae). Phytochem Rev. 2021 Jun 4:1-40. doi: 10.1007/s11101-021-09761-5. [PubMed:34104125 ]
- Su ZH, Gao YH, Cheng S, Wen Y, Tang XD, Li MW, Wu YC, Wang XY: Identification of the in vitro antiviral effect of BmNedd2-like caspase in response to Bombyx mori nucleopolyhedrovirus infection. J Invertebr Pathol. 2021 Jul;183:107625. doi: 10.1016/j.jip.2021.107625. Epub 2021 May 29. [PubMed:34058216 ]
- Hashimoto A, Handa H, Hata S, Tsutaho A, Yoshida T, Hirano S, Hashimoto S, Sabe H: Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. Cell Commun Signal. 2021 May 17;19(1):54. doi: 10.1186/s12964-021-00733-y. [PubMed:34001163 ]
- Hwang, B. Y., et al. (2004). Hwang, B. Y., et al, J. Org. Chem. 69, 3350 (2004). J. Org. Chem..
|
|---|